Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21357734 | 0.91 | CYP3A4 (0.32) | — | |
| SCHEMBL2790558 | 0.87 | NOS2 (0.33) | MAP3K7TAB1 | |
| SCHEMBL1161686 | 0.86 | CYP3A4 (0.31) | — | |
| SCHEMBL14634845 | 0.85 | — | — | |
| SCHEMBL833709 | 0.85 | ALDH1A1 (0.36) | MAP3K7TAB1 | |
| SCHEMBL262238 | 0.85 | ALDH1A1 (0.36) | MAP3K7TAB1 | |
| SCHEMBL3846863 | 0.85 | ALDH1A1 (0.36) | MAP3K7TAB1 | |
| SCHEMBL6810243 | 0.85 | — | — | |
| SCHEMBL9832443 | 0.85 | SLC7A5 (0.34) | MAP3K7TAB1 | |
| SCHEMBL1994353 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4508087-A1 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE | Genentech, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4508086-A1 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | Genentech, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119384432-A | Pharmaceutical compositions of therapeutic proteins and methods of use | 基因泰克公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240408009-A1 | CLINICAL FORMULATIONS OF ANTI-TIGIT ANTIBODIES | GENENTECH INC (US) | 2024-12-12 | — | — | US | disclosed |
| CN-119013299-A | Mo Suni tobulab pharmaceutical compositions and methods of use | 基因泰克公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4452320-A1 | CLINICAL FORMULATIONS OF ANTI-TIGIT ANTIBODIES | GENENTECH, INC. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118871131-A | Clinical formulations of anti-TIGIT antibodies | 基因泰克公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240209111-A1 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | GENENTECH INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11958906-B2 | Pharmaceutical compositions of mosunetuzumab and methods of use | GENENTECH, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230406930-A1 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE | GENENTECH, INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2023201299-A1 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023201291-A1 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | GENENTECH, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230331861-A1 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023122665-A1 | CLINICAL FORMULATIONS OF ANTI-TIGIT ANTIBODIES | GENENTECH, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220125928-A1 | COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220064315-A1 | MULTIVALENT AND MULTIEPITOPIC ANTIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE | GENENTECH, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3946457-A1 | COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS | Genentech, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406930-A1 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE | SERPINA6, TTR, CHLSN | MAP3K7 4206/4885TAB1 4597/4885 |
| US-20220064315-A1 | MULTIVALENT AND MULTIEPITOPIC ANTIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE | HAVCR2, CD4, FCGR1A | MAP3K7 3559/4885TAB1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.